Low levels of donor-specific antibodies increase risks for transplant recipients

Kidney transplant recipients who have even very low levels of preformed antibodies directed against a donated kidney have a significantly increased risk of organ rejection and kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings could help clinicians provide better donor-recipient matches and tailor recipients' immunosuppressive therapy after transplantation.

Transplant recipients who have had previous transplants, blood transfusions, and other sensitizing events often have antibodies directed against a particular donor's kidney. These antibodies can increase the risk of and . But at what level do these antibodies put recipients at increased risk? Some newer tests, called solid phase assays, can detect them at much lower blood concentrations than traditional tests.

To investigate, Sumit Mohan, MD, Amudha Palanisamy, MD (Columbia University Medical Center) and their colleagues pored through the to find studies that looked at the of with such preformed donor-specific antibodies. Their search identified seven studies that included 1,119 patients.

Together, the results of these studies suggest that the detection of donor-specific antibodies by newer tests, despite negative results from older tests, nearly doubles the risk for antibody-mediated rejection and increases the risk of kidney failure by 76%. (The absolute risk of failure in the first year in the United States is currently about 8.2% for first-time recipients and about 10.7% for repeat transplant recipients.)

"Our study quantifies the level of risk associated with antibodies detected at the time of transplantation, helping clinicians better understand the prognosis and the risk of failure, thereby allowing for appropriate tailoring of immunosuppressive therapy," said Dr. Mohan. It also suggests that donor selection processes should take into consideration the presence of antibodies in the recipient, as identified by newer, more sensitive tests.

More information: The article, entitled "Donor-Specific Antibodies Adversely Impact Kidney Allograft Outcomes," will appear online on November 15, 2012, doi: 10.1681/2012070664

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Using feminist theory to understand male rape

2 minutes ago

Decades of feminist research have framed rape and sexual assault as a 'women's issue', leaving little room for the experiences of male victims. But a new study published in the Journal of Gender Studies suggests that feminist ...

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments